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EDITORIAL
Nitric oxide and Bartter and Gitelman syndromes
Bartter and Gitelman syndromes represent the clinical parallel, chronic inhibition of the angiotensin II type 1
manifestations of functional defects in the transporters (AT1) receptor by exogenous antagonists can cause a
of the thick ascending limb and distal convoluted tubule syndrome in animals that is very similar to Bartter syn-
and are associated with volume depletion and consequent drome in humans [10].
elevated plasma renin activity, angiotensin II generation, While overt salt wasting and clinically severe hypoten-
and aldosterone excretion [1]. The mechanistic implica- sion can be life-threatening manifestations of the neona-
tions of these human genetic disorders have been con- tal forms of Bartter syndrome [11], in older patients and
firmed in transgenic mouse models of the human disease adults, potassium wasting in both syndromes and espe-
[2]. In these disorders, there is an absolute increase in cially magnesium wasting in Gitelman syndrome are the
aldosterone secretion, and due to the proximal defect(s), primary issues that provoke symptomatology and thera-
a continuing delivery of sodium to the downstream aldo- peutic efforts. Although it has not been critically exam-
sterone-sensitive distal nephron. Renal potassium wast- ined, it is assumed that restoration of the potassium stores
ing and hypokalemia are nearly universal findings. In improves vascular tone and systemic blood pressure. In-
addition to activation of the potassium secretory pro- hibition of cyclooxygenase can be helpful, especially in
cesses in the principal cells of the cortical collecting tu- the neonatal forms [11], and correction of hypokalemia
bule, there may also be defects in the overall potassium and prostaglandin overproduction can improve the uri-
absorptive mechanisms, especially in the thick ascending nary concentrating defect in these syndromes [12, 13].
limb. Calo` et al have described alternative approaches to
In addition to augmented renin secretion, angiotensin understanding the decreased vascular reactivity in Bart-
II generation, and aldosterone secretion appreciated in ter and Gitelman syndromes [14, 15]. It appears that
the original descriptions [3, 4], enhanced prostaglandin endothelial nitric oxide synthase (eNOS) and nitric oxide
E2 (PGE2) secretion (especially in Bartter syndrome) and production are up-regulated in these syndromes and at
resistance to the pressor effects of infused angiotensin II least part of the decreased vascular tone and reactivity
and catecholamines are associated with the generalized may be attributed to excess nitric oxide. In this issue of
reduction in vascular tone and low or low-normal sys- Kidney International, Calo` et al appear to have defined
temic blood pressure that are important features of these the precise defect [16]. Receptor-mediated activation of
syndromes [5]. Since the renal NaCl-conserving mecha- protein kinase C and subsequent generation of intracel-
nisms in the thick ascending limb or distal convoluted lular inositol-1,4,5 triphosphate (IP3) and increases in
tubule are impaired by the fundamental defect, it follows cytoplasmic calcium levels are defective in circulating
that relative hypovolemia and enhanced activity of the peripheral monocytes isolated from patients with geneti-
renin-angiotensin-aldosterone system are cardinal fea- cally confirmed Gitelman syndrome and clinically diag-
tures of these disorders [1]. nosed Bartter syndrome. The apparent defect lies in the
It has long been supposed that chronic potassium coupling of the agonist receptor (FMLP) to phospho-
depletion accounts for the decreased vascular reactivity, lipase, presumably at the level of a specific Gq member
especially in Bartter syndrome [6, 7], and the stimulation of the guanosine triphosphate (GTP)-binding protein
of renal PGE2 production and autonomic dysfunction family. mRNA levels appear to be reduced, and by-
[8] in hypokalemia support this view. In addition, the passing the apparent block with direct activation of pro-
fundamental aspects of salt wasting may have a primary tein kinase C appears to restore normal reactivity [16].
effect on cyclooxygenase II activity, especially in the macula Although quite attractive and logical, the finding would
densa [9]. The lack of optimal pressor responses to in- have been strengthened by demonstrating decreases in
fused agonists could be explained by persistently ele- the abundance and/or functionality of the Gq protein
vated circulating levels of angiotensin II and norepineph- of interest. Calo` et al suggest that the functional Gq
rine with consequent receptor desensitization [1]. In defect observed in Bartter and Gitelman syndromes is
an acquired defect and propose that hypokalemia may
be the explanation. A similar reduction in Gq has beenKey words: angiotensin II, renin secretion, prostaglandin E2, thick as-
cending limb, hypokalemia. described in pregnancy [17], and the increased renin
and aldosterone secretion and reduced vascular tone and 2001 by the International Society of Nephrology
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